Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 06 Aug 2022
US Government about to get long awaited powers on drug pricing
6 August 2022 - Pharma rarely loses in Washington. For years, the industry has successfully defeated US Government efforts to rein ...
Posted by Michael Wonder on 06 Aug 2022
Obesity drug supply delay not unusual says Novo Nordisk CEO
4 August 2022 - Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy (semagutide) on Thursday, ...
Posted by Michael Wonder on 06 Aug 2022
Patients seeking novel weight loss drugs find a ‘wild west’ of online prescribers
4 August 2022 - Briana Lawson was ready to knock her diabetes into remission. For years, the 47 year old ...
Posted by Michael Wonder on 05 Aug 2022
Health Minister Mark Butler ‘terrified’ of low GP numbers as bulk billing declines
6 August 2022 - Federal Health Minister Mark Butler has acknowledged there will be “terrible consequences” if general practice continues ...
Posted by Michael Wonder on 05 Aug 2022
FDA approves darolutamide tablets for metastatic hormone-sensitive prostate cancer
5 August 2022 - On 5 August 2022, the FDA approved darolutamide (Nubeqa, Bayer) tablets in combination with docetaxel for ...
Posted by Michael Wonder on 05 Aug 2022
FDA considering dividing Jynneos doses into fifths to increase vaccine supply
5 August 2022 - The Biden administration is considering splitting doses of the smallpox vaccine, which are being used to ...
Posted by Michael Wonder on 05 Aug 2022
FDA approves first targeted therapy for HER2 low breast cancer
5 August 2022 - Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an intravenous infusion for the treatment of ...
Posted by Michael Wonder on 05 Aug 2022
Calquence tablet formulation approved in the US across current indications
5 August 2022 - New formulation can be co-administered with gastric acid-reducing agents. ...
Posted by Michael Wonder on 05 Aug 2022
Acadia Pharmaceuticals receives complete response letter from U.S. FDA for supplemental new drug application for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis
4 August 2022 - Acadia Pharmaceuticals today announced that the company has received a complete response letter from the U.S. ...
Posted by Michael Wonder on 05 Aug 2022
Australia secures new third generation monkeypox virus vaccine
4 August 2022 - The Albanese Government has secured 450,000 doses of the new third generation monkeypox virus vaccine by Bavarian ...
Posted by Michael Wonder on 04 Aug 2022
U.S. regulators defend requiring more data on monkeypox drug
4 August 2022 - As U.S. monkeypox cases rise, U.S. health agencies in a medical journal article published on Wednesday ...
Posted by Michael Wonder on 04 Aug 2022
The patient voice – the value of patient-reported outcomes in HTA
4 August 2022 - The patient’s voice is increasingly important in securing access for therapies in markets and demonstrating how ...
Posted by Michael Wonder on 04 Aug 2022
Advanced oesophageal carcinoma: nivolumab in combination with chemotherapy or ipilimumab prolongs life compared to chemotherapy alone
1 August 2022 - The additional clinical benefit cannot be quantified because the data on health status and health-related quality ...
Posted by Michael Wonder on 04 Aug 2022
Regression models for ordinal outcomes
4 August 2022 - Ordinal logistic regression models are tailored for the analysis of ordinal outcomes. ...
Posted by Michael Wonder on 04 Aug 2022
Vaxcyte provides positive regulatory updates for VAX-24 adult and paediatric programs
4 August 2022 - Company receives FDA fast track designation for VAX-24 in adults. ...